Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyper‑excitable neurons, limits repetitive firing, and thereby reduces the propagation of abnormal electrical activity that can trigger seizures.

The dosage of Lacosamide is individualized and determined by the prescribing clinician based on the patient’s condition, response, and renal function. Healthcare professionals set the appropriate dose and infusion rate according to clinical guidelines.

Safety data for Lacosamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it may have a more favorable side‑effect profile for certain patients compared with older sodium‑channel blockers.

Lacosamide injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Lacosamide Fresenius Kabi is administered intravenously. It can be given as a slow infusion over several minutes or as a continuous infusion, depending on the clinical setting and physician’s instructions.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, respiratory depression, and the potential for suicidal thoughts or behavior. Prompt medical attention is required if any of these events occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction abnormalities, severe renal impairment, or uncontrolled psychiatric conditions.